Rapid Growth Tubulis GmbH has secured a record $361 million in Series C funding, reflecting strong investor confidence and rapid expansion potential, making it a promising partner for collaborations in advanced ADC technologies.

Innovative Pipeline With the first program from its 2023 licensing deal entering clinical development and recent data presentation at ESMO 2025, Tubulis demonstrates a compelling pipeline for next-generation antibody drug conjugates targeting cancer.

Strategic Leadership The appointment of Gary Fuchs as Chief Medical Officer highlights a focus on strengthening clinical strategy and pipeline development, presenting opportunities for partners seeking expertise in clinical advancement and regulatory pathways.

Partnership Opportunities Active collaborations with major pharma companies like Bristol Myers Squibb and recent investments from prominent firms open avenues for licensing, joint development, and technology licensing collaborations in ADC innovation.

Market Presence Participation in major industry events and high-profile funding rounds position Tubulis as a key industry player, making it a strategic target for sales of biotech tools, research services, or technological solutions that support drug development.